Почетна › Рак крви › Masachuset
Kliničke studije za Рак крви u državi Masachuset
28 studija za Рак крви traži učesnike na lokacijama u državi Masachuset.
Gradovi u državi Masachuset
Zvanični tekst studije (na engleskom)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03816345Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- MGH, Boston
- University of Massachusetts, Worcester
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07007312Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 4. 11. 2026. · NCT04242095HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06487247A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06697184Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
- Massachusetts General Hospital, Boston
Тражи се учесникРана фаза 1
Узраст од 18 до 70 · Оба пола · Ажурирано 14. 10. 2026. · NCT07358195Assessing DCog Short for Neurotoxicity in CAR-T
- Beth Israel Deaconess Medical Center, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07403812CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT03328078Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
- Massachusetts General Hospital, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2026. · NCT06910969SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton
- Dana-Farber Cancer Instiute - Merrimack Valley, Methuen
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT05375643(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 15. 9. 2026. · NCT04996875Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT04588922Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 8. 2026. · NCT06001788InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
- Dana Farber Cancer Institute, Boston
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Сви узрасти · Оба пола · Ажурирано 17. 8. 2026. · NCT05463796PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- Brigham and Women's Hospital, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 8. 2026. · NCT06665100Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
- Dana-Farber Cancer Institute, Boston
Тражи се учесникЗдраве особе су добродошле
Узраст 18 и старији · Оба пола · Ажурирано 16. 7. 2026. · NCT06469307Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
- Tufts Medical Center, Boston
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 7. 2026. · NCT06652633A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 6. 7. 2026. · NCT01351545IVIG for Infection Prevention After CAR-T-Cell Therapy
- Massachusetts General Hospital Cancer Center, Boston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT05952804Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- и још 2
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 7. 5. 2026. · NCT02269592Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 13 и старији · Оба пола · Ажурирано 5. 5. 2026. · NCT04771572Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation
- Massachusetts General Hospital, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 24. 4. 2026. · NCT06676852Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 21. 4. 2026. · NCT05646576A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 3. 2026. · NCT05735184A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 5. 2. 2026. · NCT07148180BMT-CARE: Psychosocial Intervention for Transplant Caregivers
- Massachusetts General Hospital Cancer Center, Boston
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2025. · NCT06472089Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 15. 4. 2025. · NCT06462365Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
Тражи се учесникФаза 1
Узраст од 1 до 21 · Оба пола · Ажурирано 6. 12. 2024. · NCT05476770Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.